Allergan’s Juvederm Dermal Filler Approved, But Market Will Wait
This article was originally published in The Gray Sheet
Executive Summary
Although Allergan's Juvederm dermal filler was approved by FDA ahead of schedule, the firm does not plan to market the cosmetic device immediately
You may also be interested in...
Allergan integrates Juvederm supplier
Allergan will pay $216 mil. to acquire French firm Groupe Corneal Laboratoires - supplier of the firm's Juvederm next-generation hyaluronic acid dermal filler products - under a Nov. 1 agreement. Allergan, which previously held exclusive marketing rights to Juvederm and future product line extensions in the U.S., Canada and Australia, now gains exclusive rights to the technology worldwide. The deal also gives the firm control over future development and manufacturing of Juvederm and related hyaluronic acid dermal fillers. Allergan gained its initial rights to the injectable facial wrinkle treatment via its March purchase of aesthetic device maker Inamed and plans a January 2007 launch following FDA approval in June (1"The Gray Sheet" June 12, 2006, p. 15). The GCL deal is expected to close in the first quarter of 2007. Drug and device maker Allergan reported Q3 device sales of $116.3 mil. - all from Inamed - representing 15% of its $791.7 mil, in corporate sales...
Allergan integrates Juvederm supplier
Allergan will pay $216 mil. to acquire French firm Groupe Corneal Laboratoires - supplier of the firm's Juvederm next-generation hyaluronic acid dermal filler products - under a Nov. 1 agreement. Allergan, which previously held exclusive marketing rights to Juvederm and future product line extensions in the U.S., Canada and Australia, now gains exclusive rights to the technology worldwide. The deal also gives the firm control over future development and manufacturing of Juvederm and related hyaluronic acid dermal fillers. Allergan gained its initial rights to the injectable facial wrinkle treatment via its March purchase of aesthetic device maker Inamed and plans a January 2007 launch following FDA approval in June (1"The Gray Sheet" June 12, 2006, p. 15). The GCL deal is expected to close in the first quarter of 2007. Drug and device maker Allergan reported Q3 device sales of $116.3 mil. - all from Inamed - representing 15% of its $791.7 mil, in corporate sales...
Allergan’s Juvederm gets multi-center trial
Allergan's hyaluronic acid dermal filler products Juvederm Ultra and Juvederm Ultra Plus commence a multi-center, open-label trial designed to gain information on physicians' use of the products. FDA approved the Juvederm fillers in June, and the firm plans a January 2007 national launch. The fillers join Allergan's Botox botulinum toxin type A in its portfolio of physician-dispensed facial aesthetics. Allergan acquired the products in March as part of its acquisition of Inamed (1"The Gray Sheet" June 12, 2006, p. 15)...